The Worldwide Cervical Cancer Screening Market was valued at US$ 26.7 Billion in 2022
Cervical Cancer Screening Market is expected to be US$ 34.92 Billion by 2028 according to the publisher. One of the most prevalent cancers in women worldwide is cervical cancer, and improving patient outcomes requires early screening and identification. The market for cervical cancer screening, which offers goods and services to identify and prevent cervical cancer, is expanding quickly. Cervical cancer is most commonly diagnosed in women between the ages of 35 and 44, with an average age of diagnosis of 50. There is an increasing need for reliable screening techniques due to the rising frequency of cervical cancer.
Increased public awareness, the aging population's expansion, and technological breakthroughs in screening have all been significant drivers of the cervical cancer screening industry. There is a higher demand for cervical cancer screening services because governments and nonprofit organizations aggressively promote screening programs and raise public awareness. In addition, given that older women have a higher chance of acquiring cervical cancer, the aging population is also anticipated to increase the demand for services for cervical cancer screening.
Cervical Cancer Screening Market is expected to grow at a CAGR of 4.57% from 2022 to 2028
There are invasive and non-invasive screening techniques available in the cervical cancer screening market. Colposcopy and biopsy are invasive procedures, although pap smears and HPV tests are not. Cervical cancer is detected using one of three screening methods. There are tests for Pap Smears, Human Papilloma Virus (HPV), and visual inspection with acetic acid (VIA). The most prevalent screening method for cervical cancer is the pap smear, which has been around for a while. HPV testing, on the other hand, is more accurate and can detect precancerous lesions early. Thus its use has recently expanded.
Given that HPV is virtually always the cause of cervical cancer, the HPV test has been approved as a second screening test for the disease (human papillomavirus). A high-risk HPV infection is more likely to result in cervix pre-cancers and cancers, as determined by the HPV test. It is possible to utilize the HPV test in conjunction with the Pap test or alone (primary HPV test) (called a co-test). As per this research report, Worldwide Cervical Cancer Screening Market was valued at US$ 26.7 Billion in 2022.
North America holds the highest share of Pap Smear and the HPV Market
The market for cervical cancer diagnostic tests worldwide was dominated by North America, Europe, Asia Pacific and Rest of the World. The American Cancer Society revealed both encouraging and alarming 2023 cancer statistics due to significant recent advancements in cancer prevention and screening in the United States (ACS). There will be 609,820 cancer deaths and 1,958,310 new cancer cases in the US in 2023, according to the American Cancer Society. The cervical cancer screening market in the US is a billion-dollar sector with a wide range of participants, including medical technology firms, insurance companies, diagnostic labs, and healthcare providers.
Cervical Cancer screening technology advancements have also significantly influenced the global cancer screening industry. The advent of new, more sensitive tests has boosted the accuracy of cervical cancer screening, resulting in earlier diagnosis and better patient outcomes. As a result, countries such as China, the United States, Canada, Japan, Korea, Singapore, India, Malaysia, Indonesia, Thailand, and the rest of the world are focusing on the early detection and prevention of cervical cancer illness. Other nations collaborating in this initiative include France, the United Kingdom, Germany, Italy, Spain, Sweden, Switzerland, Norway, the Netherlands, and the United States.
The cervical cancer screening market is likely to expand more in the next years, owing to rising public awareness, an older population, and technological developments. With the rising frequency of cervical cancer, women must be screened on a regular basis to detect and prevent the illness at an early stage. The cervical cancer screening market offers a variety of goods and services to assist women in obtaining the treatment they require to enhance their health outcomes.
Company Analysis
Companies are also investing in research and development to create new screening technologies that can detect cervical cancer at an even earlier stage. Some companies operate in the cervical cancer screening market, including Abbott Laboratories, Becton, Siemens AG, Quest Diagnostics, Roche, Hologic Corporation, and Cardinal Health.
The official release of a 'human papillomavirus (HPV) self-sampling solution' in the areas accepting the CE mark will occur in June 2022, according to F. Hoffmann-La Roche Ltd., a multinational healthcare corporation based in Switzerland. The main benefit of this test kit is HPV screening, which can identify women at an increased risk of getting cervical cancer.
Supplier of in-vitro diagnostics SANSURE BIOTECH INC. announced in January 2022 that the China National Medical Products Administration had approved its 'HPV DNA Diagnostic Kit (HPV 13+2)' (NMPA). The kit was created using cutting-edge magnetic bead technology and more than 13 different high-risk genotypes to guarantee that it can screen for cervical cancer.
According to the publisher report 'Cervical Cancer Market, Patients Population Global Forecast by Tests (Pap Smear, HPV DNA, VIA), 20 Countries (United Kingdom, France, Germany, Italy, Spain, Sweden, Switzerland, Norway, Netherlands, United States, Canada, Japan, Korea, Singapore, Malaysia, India, China, Indonesia, Thailand and Rest of world) Company (Abbott Laboratories, Becton, Siemens AG, Quest Diagnostics, Roche, Hologic Corporation and Cardinal Health)” provides a complete analysis of Worldwide Cervical Cancer Screening Industry.'
Cervical Cancer Screening Market & Population - the report studies all 3 types of Test
1. Pap Smear Tests Market
2. HPV DNA Tests Market
3. VIA Tests Market
Cervical Cancer Countries Covered:
1. United Kingdom
2. France
3. Germany
4. Italy
5. Spain
6. Sweden
7. Switzerland
8. Norway
9. Netherlands
10. United States
11. Canada
12. Japan
13. Korea
14. Singapore
15. Malaysia
16. India
17. China
18. Indonesia
19. Thailand
20. Rest of World
Companies have been covered from 3 viewpoints
- Overview
- Recent Development
- Sales
Company Analysis
1. Abbott Laboratories
2. Becton
3. Siemens AG
4. Quest Diagnostics
5. Roche
6. Cardinal Health
7. Hologic Corporation
Table of Contents
1. Introduction2. Research Methodology
3. Executive Summary
4. Market Dynamics
4.1 Growth Drivers
4.2 Challenges
5. Global Cervical Cancer Test (Screening) Population
5.1 North America
5.2 Europe
5.3 Asia
5.4 Rest of World
6. Global Cervical Cancer Test (Screening) Market
6.1 Pap Smear Test (Screening)
6.2 HPV DNA Test (Screening)
7. Region - Global Cervical Cancer Test (Screening) Market Analysis
7.1 North America
7.2 Europe
7.3 Asia
7.4 Rest of World
8. Population Share - Global Cervical Cancer Test (Screening)
8.1 By Region
8.2 By Countries
9. Market Share - Global Cervical Cancer Test (Screening)
9.1 Region - Cervical Cancer Test (Screening)
9.2 Countries - Cervical Cancer Test (Screening)
9.3 Countries - Pap Smear Test (Screening)
9.4 Countries - HPV DNA Test (Screening)
9.5 Countries - VIA Test (Screening)
10. United Kingdom - Cervical Cancer Test Analysis
10.1 United Kingdom Cervical Cancer Test (Screening) Population
10.1.1 United Kingdom Pap Smear Test Population
10.1.2 United Kingdom HPV DNA Test Population
10.2 United Kingdom Cervical Cancer Test (Screening) Market
10.2.1 United Kingdom Pap Smear Test Market
10.2.2 United Kingdom HPV DNA Test Market
11. France - Cervical Cancer Test Analysis
11.1 France Cervical Cancer Test (Screening) Population
11.1.1 France Pap Smear Test Population
11.1.2 France HPV DNA Test Population
11.2 France Cervical Cancer Test (Screening) Market
11.2.1 France Pap Smear Test Market
11.2.2 France HPV DNA Test Market
12. Germany - Cervical Cancer Test Analysis
12.1 Germany Cervical Cancer Test (Screening) Population
12.1.1 Germany Pap Smear Test Population
12.1.2 Germany HPV DNA Test Population
12.2 Market - Cervical Cancer Test (Screening)
12.2.1 Germany Pap Smear Test Market
12.2.2 Germany HPV DNA Test Market
13. Italy - Cervical Cancer Test Analysis
13.1 Cervical Cancer Test (Screening) Population
13.1.1 Italy Pap Smear Test Population
13.1.2 Italy HPV DNA Test Population
13.2 Italy Cervical Cancer Test (Screening) Market
13.2.1 Italy Pap Smear Test Market
13.2.2 Italy HPV DNA Test Market
14. Spain - Cervical Cancer Test Analysis
14.1 Spain Cervical Cancer Test (Screening) Population
14.1.1 Spain Pap Smear Test Population
14.1.2 Spain HPV DNA Test Population
14.2 Spain Cervical Cancer Test (Screening) Market
14.2.1 Spain Pap Smear Test Market
14.2.3 Spain HPV DNA Test Market
15. Sweden - Cervical Cancer Test Analysis
15.1 Sweden Cervical Cancer Test (Screening) Population
15.1.1 Sweden Pap Smear Test Population
15.1.2 Sweden HPV DNA Test Population
15.2 Cervical Cancer Test (Screening) Market
15.2.1 Sweden Pap Smear Test Market
15.2.2 Sweden HPV DNA Test Market
16. Switzerland - Cervical Cancer Test Analysis
16.1 Switzerland Cervical Cancer Test (Screening) Population
16.1.1 Switzerland Pap Smear Test Population
16.1.2 Switzerland HPV DNA Test Population
16.2 Switzerland Cervical Cancer Test (Screening) Market
16.2.1 Switzerland Pap Smear Test Market
16.2.2 Switzerland HPV DNA Test Market
17. Norway - Cervical Cancer Test Analysis
17.1 Norway Cervical Cancer Test (Screening) Population
17.1.1 Norway Pap Smear Test Population
17.1.2 Norway HPV DNA Test Population
17.2 Norway Cervical Cancer Test (Screening) Market
17.2.1 Norway Pap Smear Test Market & Forecast
17.2.2 Norway HPV DNA Test Market
18. Netherlands - Cervical Cancer Test Analysis
18.1 Netherlands Cervical Cancer Test (Screening) Population
18.1.1 Netherlands Pap Smear Test Population
18.1.2 Netherlands HPV DNA Test Population
18.2 Netherlands Cervical Cancer Test (Screening) Market
18.2.1 Netherlands Pap Smear Test Market
18.2.2 Netherlands HPV DNA Test Market
19. United States - Cervical Cancer Test Analysis
19.1 United States Cervical Cancer Test (Screening) Population
19.1.1 United States Pap smear Test Population
19.1.2 United States HPV DNA Test Population
19.2 United States Cervical Cancer Test (Screening) Market
19.2.1 United States Pap Smear Test Market
19.2.2 United States HPV DNA Test Market
20. Canada - Cervical Cancer Test Analysis
20.1 Canada Cervical Cancer Test (Screening) Population
20.1.1 Canada Pap smear Test Population
20.1.2 Canada HPV DNA Test Population
20.2 Canada Cervical Cancer Test (Screening) Market
20.2.1 Canada Pap Smear Test Market
20.2.2 Canada HPV DNA Test Market
21. Japan - Cervical Cancer Test Analysis
21.1 Japan Cervical Cancer Test (Screening) Population
21.1.1 Japan Pap smear Test Population
21.1.2 Japan HPV DNA Test Population
21.2 Japan Cervical Cancer Test (Screening) Market
21.2.1 Japan Pap Smear Test Market
21.2.2 Japan HPV DNA Test Market
22. South Korea - Cervical Cancer Tests Analysis
22.1 South Korea - Cervical Cancer Test (Screening) Population
22.1.1 South Korea Pap Smear Test Population
22.1.2 Korea HPV DNA Test Population
22.2 Korea Cervical Cancer Test (Screening) Market
22.2.1 Korea Pap Smear Test Market
22.2.2 Korea HPV DNA Test Market
23. Singapore - Cervical Cancer Tests Analysis
23.1 Singapore - Cervical Cancer Test (Screening) Population
23.1.1 Singapore Pap Smear Test Population
23.1.2 Singapore HPV DNA Test Population
23.2 Singapore Cervical Cancer Test (Screening) Market
23.2.1 Singapore Pap Smear Test Market
23.2.2 Singapore HPV DNA Test Market
24. Malaysia - Cervical Cancer Test Analysis
24.1 Malaysia - Cervical Cancer Test (Screening) Population
24.1.1 Malaysia Pap Smear Test Population
24.1.2 Malaysia HPV DNA Test Population
24.2 Malaysia Cervical Cancer Test (Screening) Market
24.2.1 Malaysia Pap Smear Test Market
24.2.2 Malaysia HPV DNA Test Market
25. India - Cervical Cancer Test Analysis
25.1 India - Cervical Cancer Test (Screening) Population
25.1.1 India Pap Smear Test Population
25.1.2 India HPV DNA Test Population
25.1.3 India VIA Test Population
25.2 India Cervical Cancer Test (Screening) Market
25.2.1 India Pap Smear Test Market
25.2.2 India HPV DNA Test Market
25.2.3 India VIA Test Market
26. China - Cervical Cancer Test Analysis
26.1 China - Cervical Cancer Test (Screening) Population
26.1.1 China Pap Smear Test Population
26.1.2 China HPV DNA Test Population
26.1.3 China VIA Test Population
26.2 China - Cervical Cancer Test (Screening) Market
26.2.1 China Pap Smear Test Market
26.2.2 China HPV DNA Test Market
26.2.3 China VIA Test Market
27. Thailand - Cervical Cancer Test Analysis
27.1 Thailand - Cervical Cancer Test (Screening) Population
27.1.1 Thailand Pap Smear Test Population
27.1.2 Thailand VIA Test Population
27.2 Thailand Cervical Cancer Test (Screening) Market
27.2.1 Thailand Pap Smear Test Market
27.2.2 Thailand VIA Test Market
28. Indonesia - Cervical Cancer Test Analysis
28.1 Indonesia Cervical Cancer Test (Screening) Population
28.1.1 Indonesia Pap Smear Test Population
28.1.2 Indonesia HPV DNA Test Population
28.1.3 Indonesia VIA Test Population
28.1.4 Indonesia Pap Smear & VIA Test Population
28.2 Indonesia Cervical Cancer Test (Screening) Market
28.2.1 Indonesia Pap Smear Test Market
28.2.2 Indonesia HPV DNA Test Market
28.2.3 Indonesia VIA Test Market
28.2.4 Indonesia Pap smear & VIA Test Market
29. Rest of World - Cervical Cancer Test Analysis
29.1 Rest of World Cervical Cancer Test (Screening) Population
29.1.1 Rest of World Pap smear Test Population
29.1.2 Rest of World HPV DNA Test Population
29.2 Rest of World Cervical Cancer Test (Screening) Market
29.2.1 Rest of World Pap Smear Test Market
29.2.2 Rest of World HPV DNA Test Market
30. Company Analysis
30.1 Abbott laboratories
30.1.1 Overview
30.1.2 Recent Development
30.1.3 Revenue
30.2 Hologic Corporation
30.2.1 Overview
30.2.2 Recent Development
30.2.3 Revenue
30.3 Becton
30.3.1 Overview
30.3.2 Recent Development
30.3.3 Revenue
30.4 Siemens AG
30.4.1 Overview
30.4.2 Recent Development
30.4.3 Revenue
30.5 Roche Diagnostics
30.5.1 Overview
30.5.2 Recent Development
30.5.3 Revenue
30.6 Quest Diagnostics
30.6.1 Overview
30.6.2 Recent Development
30.6.3 Revenue
30.7 Cardinal Health
30.7.1 Overview
30.7.2 Recent Development
30.7.3 Revenue
Companies Mentioned
- Abbott Laboratories
- Becton
- Siemens AG
- Quest Diagnostics
- Roche
- Cardinal Health
- Hologic Corporation
Methodology
In this report, for analyzing the future trends for the studied market during the forecast period, the publisher has incorporated rigorous statistical and econometric methods, further scrutinized by secondary, primary sources and by in-house experts, supported through their extensive data intelligence repository. The market is studied holistically from both demand and supply-side perspectives. This is carried out to analyze both end-user and producer behavior patterns, in the review period, which affects price, demand and consumption trends. As the study demands to analyze the long-term nature of the market, the identification of factors influencing the market is based on the fundamentality of the study market.
Through secondary and primary researches, which largely include interviews with industry participants, reliable statistics, and regional intelligence, are identified and are transformed to quantitative data through data extraction, and further applied for inferential purposes. The publisher's in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of their recommendations and advice.
Primary Research
The primary purpose of this phase is to extract qualitative information regarding the market from the key industry leaders. The primary research efforts include reaching out to participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions. The publisher also established professional corporate relations with various companies that allow us greater flexibility for reaching out to industry participants and commentators for interviews and discussions, fulfilling the following functions:
- Validates and improves the data quality and strengthens research proceeds
- Further develop the analyst team’s market understanding and expertise
- Supplies authentic information about market size, share, growth, and forecast
The researcher's primary research interview and discussion panels are typically composed of the most experienced industry members. These participants include, however, are not limited to:
- Chief executives and VPs of leading corporations specific to the industry
- Product and sales managers or country heads; channel partners and top level distributors; banking, investment, and valuation experts
- Key opinion leaders (KOLs)
Secondary Research
The publisher refers to a broad array of industry sources for their secondary research, which typically includes, however, is not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Patent and regulatory databases for understanding of technical & legal developments
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic new articles, webcasts, and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecasts
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 600 |
| Published | February 2023 |
| Forecast Period | 2022 - 2028 |
| Estimated Market Value ( USD | $ 26.7 Billion |
| Forecasted Market Value ( USD | $ 34.92 Billion |
| Compound Annual Growth Rate | 4.5% |
| Regions Covered | Global |
| No. of Companies Mentioned | 7 |
